TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...

The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response. The Food and Drug Administration (FDA) has ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...

A few reasons why the want-to-be cholesterol blockbuster Praluent will not be as much of a "budget buster" as the medicine that cures most hepatitis C patients. From the New York Times (New Drug ...

The FDA has recently approved a drug to help patients who have been unable to adequately lower their cholesterol through conventional treatments. It's going by the brand name Praluent, and it's ...

DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...